Posts Tagged ‘ubrogepant’
Anti-CGRP Treatment Improves Prodromal Symptoms of Migraine
A new phase 3 clinical trial shows that ubrogepant, a CGRP receptor antagonist, alleviates photophobia, fatigue, neck pain, and other prodromal symptoms.
Read MoreMid-Year Update: What Have You Been Reading on Migraine Science Collaborative in 2024?
Our Top 5 list reflects interest in new approaches to treating headache.
Read MoreTreating Migraine Before It Begins with a CGRP Inhibitor
A new trial shows that ubrogepant, a small-molecule calcitonin gene-related peptide receptor antagonist, prevents headache when taken during the prodrome phase. The findings have large clinical implications.
Read More